PATENT ABSTRACTS 323

Accession Nos. B-18462, B-18463, and B-18464. The probes are sufficiently sensitive to detect hardjo-bovis in as few as l* 102 cells/ml. The dia- gnostic capabilities of the probes render them useful not only as herd management tools, but also in epidemiology studies designed to deter- mine the origin and migration of L. interrogans isolates.

5091302

POLYMORPHISM OF HUMAN PLATELET MEMBRANE

GLYCOPROTEIN IIIA AND DIAGNOSTIC AND

THERAPEUTIC APPLICATIONS THEREOF

Peter J Newman, Richard Aster assigned to The Blood Center of Southeastern Wisconsin Inc

Isolated polynucleotide molecules, and peptides encoded by those molecules, can be used in the analysis of alloantigen phenotypes, as well as in diagnostic and therapeutic applications relating to human platelet PIA polymorphism. In this vein, a method for typing blood cell and platelet membrane glycoproteins entails an analysis of amplified cDNA, encoded by platelet and red blood cell mRNA.

5091304

WHOLE BLOOD ACTIVATED PARTIAL THROMBOPLASTIN

TIME TEST AND ASSOCIATED APPARATUS

Frank M La Duca, Eduardo I Marcelino as- signed to International Technidyne Corporation

An activated partial thromboplastin time (APTT) test is described which does not require blood which has been anticoagulated with ci- trate. The test enables the citrate anticoagulant step to be combined with the contact activation step and hence enables one to employ fresh non- anticoagulated blood specimens to directly perform the APTT Test.

5091308

PROCESS FOR THE ENZYMATIC DISPERSAL OF

MYCOBACTERIUM BOVIS - BCG

Melvin E Klegerman, Michael Groves assigned

to The Board of Trustees of the University of II- linois

Mycobacterium bovis BCG suspensions are treated with a protease enzyme such as pronase, resulting in the production of suspensions having smaller aggregates and single cells. Such suspensions, when processed into vaccines, ex- hibit improved immunizing potential against cancer and would be expected to exhibit im- proved immunizing potential against tuber- culosis.

5091363

AGENT FOR THE THERAPY OF FACTOR VIII-RESISTANT HEMOPHILIA A, AND A

PROCESS FOR THE PREPARATION THEREOF

Norber Heimburger, Karlheinz Wenz, Wilfried Wormsbacher, Marburg, Federal Republic Of Germany assigned to Behringwerke Ak- tiengesellschaft

An agent for the therapy of hemophilia A which is resistant to treatment with factor VIII is described, and is obtainable by maintaining a mixture of factor VIII, antithrombin III, a phospholipid and calcium ions in an aqueous solution at a temperature of from 1 degrees to 45 degrees C. for at least one minute, adding factor IX, and maintaining the solution at a tempera- ture offrom 1 degrees to 45 degrees C. until addi- tion of a sample of this solution to an inhibitor plasma results in a partial thromboplastin time (PTT) of 15 to 30 seconds, where appropriate adding a polyol and, where appropriate, an amino acid, and, where appropriate, drying the solution.

5091364

PREPARATION OF IMMUNOLOGICALLY ACTIVE

CELL WALL COMPONENTS FROM ARCHAEBACTERIA

Jorg Baumgarten, Helmut Brnnner, Inge Flesch, Heinz Hildebrand, Norbert Piel, Michael Sper- zel, Wuppertal, Federal Republic Of Germany assigned to Bayer Aktiengesellschaft

A process for the preparation of glycoproteins and proteins from cultures of archaebacteria, comprising culturing archaebacteria, isolating glycoprotein and/or protein from the archaebac- teria or their cell walls, enzymatically degrading

324 PATENT ABSTRACTS

the glycoprotein and/or protein, purifying and isolating the degradation products, and separating those fractions in the individual purification steps based on the biological activity of the fraction. The products increase the body’s defenses against infection.

5091374

DOUBLE-STRANDED RNA CORRECTION OF

ABNORMALITIES IN CIRCULATING IMMUNE

COMPLEXES AND MONOCYTE FUNCTION

William A Carter assigned to HEM Research Inc

Abnormalities in the circulating immune com- plexes in a patient’s blood, such as observed in patients having inflammatory disorders, viral in- fections, or simply deranged immune function, are restored to normal or viral immunity con- ferred by the administration of a matched or mismatched dsRNA.

5091376

NON-CAPSULE EXOPOLYSACCHARIDE FROM

ZOOGLOEA RAMIGERA

Donald Easson, Oliver P Peoples, Anthony Sinskey assigned to Massachusetts Institute of Technology

Two new bacterial strains designated Zoogloea ramigera 115SL and Zoogloea ramigera I ISSLR, a rifampicin resistant derivative of 115SL, have been developed. These strains are derived from the wild type Zoogloea ramigera 115, ATCC 25935. The two new strains produce a novel exopolysaccharide (EPS) and have several desirable characteristics that are absent from the parent strain, including improved cul- ture properties, since they do not produce an EPS capsule layer like that of the parent 115 strain. The 115SL EPS is instead excreted as a slime layer which is not confined to the im- mediate area surrounding the cells. Since cells are not trapped within a floe where they grow at a reduced rate or die because of nutrient starva- tion, the new strains have more consistent and reproducible growth cycles and increased growth rates. As a consequence, ex-

opolysaccharide production is more consistent and titers are higher. The separation of the EPS from the cells is also much easier and more economical. The other very important charac- teristic of strains 115SL and 115SLR is that they are able to receive foreight DNA using conven- tional techniques due to the absence of the capsule layer. This facilitates the application of recombinant DNA technology to control and produce novel exopolysaccharides.

5091412

NOVEL ANTIVIRAL TERPENE HYDROQUINONES AND

METHODS OF USE

Amy S Wright, Sue S Cross, Neal S Burres, Frank Koehn assigned to Harbor Branch Oceanographic Institution Inc

Novel terpene hydroquinones have been isolated from the marine sponge Stronglophora hartmanii. These compounds have been found to have antiviral activity. Thus, these compounds, and derivatives thereof, can be used to treat viral infections. Additionally, the subject invention concerns the discovery that the terpene hydro- quinone known as aureol has strong antiviral ac- tivity.

5091413

ANTIBIOTIC AGENT

George M Garrity, Val Sagrario M Del, Mary Nallin, Dennis Schmatz, Jack Smith, Frank L VanMiddlesworth, Kenneth E Wilson, Marcia M Zweerink assigned to Merck & Co Inc

An antibiotic agent produced by the cultivation of Dictyochaeta simplex is described. The com- pound has broad antifungal activity and anti- pneumocystis activity.

5091511

LYMPHOKINE ACTIVATED KILLER SUPPRESSIVE FACTOR

(LAKSF), PROCESS FOR PRODUCING IT AND

IMMUNOSUPPRESSIVE AGENT COMPRISING IT

Saburo Sone, Masanobu Munekata, Akito